Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00813618 · ClinicalTrials.gov registry record · Phase 1

Study of MEDI 507 in the Treatment of Pediatric Patients

A Phase 1 study of Graft-Versus-Host Disease, sponsored by MedImmune.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
6
Study locations

NCT00813618: Completed Phase 1 study of Graft-Versus-Host Disease, sponsored by MedImmune.

NCT00813618 is a Phase 1 study of Graft-Versus-Host Disease that has completed, run by MedImmune. The registered enrollment target is 10 participants, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (88% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00813618, a Phase 1 study of Graft-Versus-Host Disease, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
6
Study locations

Study Summary

To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.

Conditions Studied

Graft-Versus-Host Disease

Interventions

  • DRUG MEDI-507

Study Locations (6)

Alabama

  • Children's Hospital - Birmingham

California

  • Children's Hospital of Orange County - Orange

Illinois

  • Children's Memorial Hospital - Chicago

Michigan

  • Univ. of Michigan Medical Center - Ann Arbor

New Jersey

  • Hackensack U. Medical Center - Hackensack

Pennsylvania

  • The Children's Hosp. of Phila., Abramson Ped. Research Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 1999-09
Est. Completion 2004-08
Phase Phase 1
MedImmune

210 total trials

What the finished NCT00813618 record still lists

NCT00813618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 1 intervention - of which MEDI-507 is the first listed.

NCT00813618 lists 6 locations in 6 states (Alabama, California, Illinois).

Frequently Asked Questions

What is clinical trial NCT00813618 about?

NCT00813618 is a clinical study titled "Study of MEDI 507 in the Treatment of Pediatric Patients". To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.

What is the current status of trial NCT00813618?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 1999-09. Estimated completion is 2004-08.

What conditions does trial NCT00813618 study?

This clinical trial studies the following conditions: Graft-Versus-Host Disease.

What interventions are being tested in trial NCT00813618?

The interventions under investigation include: MEDI-507 (DRUG).

Who is sponsoring clinical trial NCT00813618?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00813618 being conducted?

This trial has 6 study locations across Alabama, California, Illinois, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Graft-Versus-Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00813618's enrollment target sits among peer trials

10 37th of 38 higher than 2 of 38 other Graft-Versus-Host Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Graft-Versus-Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00813618, the US trial registry maintained by the National Library of Medicine. NCT00813618 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.